Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial

Related articles

1. Safety and Preliminary Efficacy of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells (GXIPC1) in Patients with Type 1 Diabetes Mellitus: A Phase 1, Single-Arm, Open-Label Clinical Trial

   This article has 12 authors:

   1. Liem T. Nguyen
   2. Hoan T. Nguyen
   3. Kien T. Nguyen
   4. Van T. Hoang
   5. Trang T.K. Phan
   6. Anh T.P. Nguyen
   7. Thu A. Ha
   8. Ruei-Yue Liang
   9. Po-Cheng Lin
   10. Yu-Chen Tsai
   11. Chun-Hung Chen
   12. Ming-Hsi Chuang

2. Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: single-arm, open-label, phase I study

   This article has 13 authors:

   1. Kai Hu
   2. Fan Yang
   3. Rui Liu
   4. Zhonghua Fu
   5. Yuelu Guo
   6. Lixia Ma
   7. Miaomiao Cao
   8. Biping Deng
   9. Alex H. Chang
   10. Haifeng Wu
   11. Shilin Gan
   12. Chen Chen
   13. Xiaoyan Ke

3. Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease

   This article has 10 authors:

   1. Xin Li
   2. Can Liu
   3. Siyan Niu
   4. Ru Li
   5. Shuquan Gao
   6. Rui Cui
   7. Jia Wang
   8. Yao Qi
   9. Jingyi Li
   10. Qi Deng